Consistent with the current finding, previous studies on esophageal squamous cell carcinoma, breast cancer and colorectal cancer demonstrated that loss of Smad2 expression is correlated with tumor development and poor prognosis [23], [24], [25], [26]. Here, SMAD2 is linked to breast carcinoma.